Next Jump

Beacon Therapeutics is an ophthalmic gene therapy company based in Cambridge, MA. They are dedicated to saving and restoring the vision of patients with a wide range of prevalent and rare retinal diseases that lead to blindness. Their pioneering ocular gene therapy approach involves modifying a patient's cells by adding a functional copy of the mutated gene responsible for the disease, allowing the body to produce proteins to treat or prevent genetic conditions. With a focus on diseases such as X-Linked Retinitis Pigmentosa, Dry Age-related Macular Degeneration, and Cone Rod Dystrophy, Beacon Therapeutics aims to provide long-lasting benefits and improve the quality of life for patients. Through their bold science and ongoing clinical trials, Beacon Therapeutics offers a real hope for lasting treatments for severe forms of genetic blindness. Their innovative gene therapy approach has shown significant gains in vision in recent studies, providing a glimmer of hope for those affected by these devastating eye diseases. With a commitment to transforming lives and making remarkable happen, Beacon Therapeutics is at the forefront of ocular gene therapy, working towards a future where blindness can be prevented or treated effectively.Generated from the website

LiquiGlide, based in Cambridge, MA, is a pioneering surface engineering technology company that specializes in creating durable, slippery surfaces. Their innovative coatings consist of a textured solid material that traps a liquid lubricant through capillary and intermolecular forces, resulting in self-lubricating surfaces that are custom designed to adhere to a variety of materials and environmental conditions. Utilizing a proprietary algorithm and leveraging chemical affinity and capillarity, LiquiGlide's technology sets itself apart from conventional superhydrophobic surfaces by offering long-lasting slipperiness that can be tailored for food safety, industrial environments, and other specific applications. With a robust global IP portfolio and a focus on innovation, LiquiGlide is at the forefront of building a frictionless future.Generated from the website

Dragonfly Therapeutics, located in Cambridge, MA, is a clinical-stage biotech company dedicated to transforming the treatment of various diseases through innovative natural killer cell-based therapies. With proprietary platforms including TriNKETs and CYTOKINEs, Dragonfly has developed a robust pipeline with a focus on autoimmune diseases, oncology, and neuro-inflammation, targeting significant patient needs. The company has formed strategic collaborations with industry leaders like AbbVie, BMS, Gilead, and Merck, leading to the advancement of 11 drug candidates. Dragonfly aims to continuously grow its pipeline, augmenting its research in a range of therapeutic areas, including fibrotic diseases and infectious diseases, to ensure improved patient outcomes. Generated from the website